Rather than a one-size-fits-all blood test that looks for a single pathology, NeuroDex is commercializing a novel scientific approach, based on the study of extracellular vesicles – that can decipher “mixed pathology” in dementia and lead to a more personalized treatment plan. The Challenge Whenever we write about a company in the Alzheimer’s Moonshot we…
Amidst the complexity of the human body lies the key to understanding various diseases and their treatments: biomarkers. These biological indicators can reveal the state of health or the progression of a disease, making their discovery crucial in medical research. Biomarker discovery services combine cutting-edge science with an understanding of disease mechanisms to identify these…
Showcasing Pioneering Diagnostic Technologies We proudly announce that Neurodex will play a significant role at the forthcoming Bio-Neuroscience Conference, highlighting our innovative diagnostic technologies for neurodegenerative diseases. Oded Biran, our distinguished SEO, will present our leading-edge work in developing blood-based biomarkers and leveraging cell-specific extracellular vesicles (exosomes) for precise diagnostics. About Our Innovations Neurodex is…
Introduction: Neurodex is pleased to announce its participation in the upcoming 2nd Annual Meeting hosted by the American Association of Extracellular Vesicles (AAEV). Set against the picturesque backdrop of Boston, MA, this event promises to gather esteemed experts in extracellular vesicle research. Neurodex is gearing up to share its latest insights into the study of…
Cambridge, MA & Singapore, August 09, 2023 Sunbird Bio, a pioneering biotechnology company focused on advancing the diagnosis and treatment of neurological disorders and early-stage cancer through proprietary protein-based technologies, has successfully merged with Glympse Bio. The merger aims to expedite the development of the two companies protein-based diagnostic platforms, creating a powerful entity named…
Introduction: In a significant development, a committee of expert advisors to the U.S. Food and Drug Administrator has endorsed for full approval of an Alzheimer’s disease drug developed by Biogen Inc. in collaboration with Eisai. The committee’s unanimous 6-0 vote concluded that Leqembi, the drug in question, demonstrated clinical benefit for patients, meeting the prerequisite…
For application titled: “Blood Test for Parkinson’s Stratification based on Neuron and Oligodendrocyte Derived Extracellular Vesicles”NATICK, MASSACHUSETTS, UNITED STATES OF AMERICA, January 26, 2023 /EINPresswire.com/ — NeuroDex, Inc.(“NeuroDex”, or the “Company”), announces that it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to study, “Blood Test for Parkinson’s Stratification based on Neuron…